Here’s Why. The plan is to treat two thalassemia patients first, then wait for safety data before putting anyone else at risk. Let's conquer your financial goals together...faster. Better Buy: Editas Medicine or Sangamo Therapeutics? The volatility ratio for the week stands at 4.22% while the volatility levels for the past 30 days are set at 4.48% for Sangamo Therapeutics Inc.. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of $0.41 by $0.67. While we remain committed to raising the necessary funds to keep IV heading in the right direction & still plan to get back to each of our supporters individually, we ask that you accept our apologies in advance for any customer service delays caused by an immediate need to prep for yet another major hurricane (, Re: Jefferies - 1st HemA Gene Tx Ph.III Pt Dosed & Possible For PFE-SGMO To Catch Up; Model Adj - Target from $15 to $16, Re: A bit of fun - let's nominate a new name and ask in the next Q&A, A bit of fun - let's nominate a new name and ask in the next Q&A, 261 members / Company’s stock value dipped to $9.52 during the trading on the day. Sangamo promised to give us an interim look at the follow-up Alta study with SB-525 last December but decided at the last moment to hold these cards close to the vest. Both are going to have some important clinical trial readouts in 2019 that could send their share prices screaming toward the moon again. H.C. Wainwright gave a rating of “Buy” to SGMO, setting the target price at $16 in the report published on August 26th of the previous year. The company’s stock price... Chico's FAS Inc. (NYSE:CHS) went up by 5.99% from its latest closing price compared to the recent 1-year high of $5.14. Based on Sangamo Therapeutics Inc. (SGMO), the company’s capital structure generated 10.27 points at debt to equity in total, while total debt to capital is 9.31. At the time of this writing, the total market value of the company is set at 1.46B, as it employees total of 354 workers. Investchronicle.com is an Economic news website, which offers broad information about the Stock markets and Equities. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. When the trading was stopped its value was $9.70. The company’s stock price... Centennial Resource Development Inc. (NASDAQ:CDEV) went up by 1.63% from its latest closing price compared to the recent 1-year high of $5.35. Volatility was left at 4.48%, however, over the last 30 days, the volatility rate increased by 4.22%, as shares sank -4.86% for the moving average over the last 20 days. BioMarin Stock Slumps After FDA’s Surprise Rejection of a Hemophilia Gene Therapy, Sangamo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference, Sangamo Therapeutics Reports Q2 Loss, Lags Revenue Estimates, Sangamo Therapeutics Reports Business Highlights and Second Quarter 2020 Financial Results. BioMarin Files MAA to EMA for Gene Therapy of Hemophilia A, Investors Hope for More From Takeda Than a Healthy Dividend, We're Keeping An Eye On Sangamo Therapeutics's Cash Burn Rate, Sangamo Announces UK Authorization of a Phase 1/2 Clinical Trial Evaluating the CAR-Treg Cell Therapy TX200 for Kidney Transplantation, Sangamo Therapeutics Announces New Scientific Advisory Board. The company’s stock price... Lumen Technologies Inc. (NYSE:LUMN) went up by 1.92% from its latest closing price compared to the recent 1-year high of $15.30. After a couple of fruitless decades with earlier versions, Sangamo plans on releasing next-generation ZFN treatments before the end of the year. Additionally, trading for the stock in the period of the last six months notably improved by 45.85%, alongside a boost of 22.95% for the period of the last 12 months. The company’s... Sintx Technologies Inc. (NASDAQ:SINT) went up by 2.59% from its latest closing price compared to the recent 1-year high of $3.30. This experimental gene therapy involves editing a patient's stem cells outside their body with CRISPR/cas9 technology before reintroducing the cells to patients who need help producing functional hemoglobin. Reports are indicating that there were more than several insider trading activities at SGMO starting from DILLY STEPHEN GEORGE, who sale 35,000 shares at the price of $6.00 back on Mar 19. Sep 11, 2020 Sangamo Therapeutics Appoints … Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. How Many Sangamo Therapeutics, Inc. Shares Did Insiders Buy, In The Last Year? Sangamo Therapeutics had a negative return on equity of 23.12% and a negative net margin of 91.17%. Instead, the complete results will be released sometime in 2019. Will Sangamo Therapeutics Continue to Surge Higher? Pfizer's already on the hook for development expenses, and Sangamo is entitled to milestones and royalty payments that the big pharma could avoid by simply acquiring Sangamo. Biotech Stock Roundup: GILD to Buy Forty Seven, Pipeline Updates From BIIB & More, Sangamo Therapeutics Surpasses Q4 Earnings and Revenue Estimates, Sangamo Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results, Biogen pays California biotech $350M upfront for Alzheimer's gene therapy, Why This Small Gene Therapy Player Rocketed On A Biogen Deal, Sangamo Therapeutics Announces Fourth Quarter and Full Year 2019 Conference Call and Webcast. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is not the most popular stock in this group but hedge fund interest is still above average. Right now CRISPR Therapeutics' market cap is at $1.8 billion, which is a lot for a company without any human proof-of-concept data yet. It also offers complementary technology platforms such as gene therapy, ex … CRISPR spent $114 million last year on research and development before a single patient had been dosed. Summit Hotel Properties Inc. (NYSE:INN) went up by 1.89% from its latest closing price compared to the recent 1-year high of $12.59. The only reason to buy Sangamo is its proprietary synthetic liver-specific gene promoter that's also a part of SB-525, a candidate for the treatment of hemophilia A. Pfizer (NYSE:PFE) has agreed to take the reins for SB-525 if an ongoing trial hits the right mark. The company’s stock... iBio Inc. (AMEX:IBIO) went up by 2.97% from its latest closing price compared to the recent 1-year high of $7.45. Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. 4 More Biotechs Break From IPO Starting Gate. The Alkaline Water Company Inc. (NASDAQ:WTER) went up by 6.02% from its latest closing price compared to the recent 1-year high of $2.60.